METABOLIC MEASUREMENT AND MONITORING IN CLINICAL HYPERTHERMIA

该项目已经成功地研究了磁共振成像(MRI)和 31P波谱(MRS)用于评估预后和监测治疗结果 在人和狗的软组织肉瘤患者中应用 热疗(HT)加放射治疗(RT)。有很强的 在定义的数据中查找相关的生理数据配置文件的基本原理 一组肿瘤，处于未受干扰的状态和治疗后 干预以提高我们对生理机制的理解 对热放射治疗的临床反应。这样的生理代谢 数据可以极大地帮助开发和部署反 肿瘤治疗，特别是如果这些信息可以被证明是 独立于其他已知的预后变量。 具体地说，我们需要(L)能够在治疗前识别这些 最有可能从特定疗程中受益的患者，(2)至 在治疗过程中及早确定无反应的患者 谁的治疗替代方案能够以最大的疗效实施。 这项研究的目标是继续评估肿瘤的有用性 生理特征，如31P MRS，1H MRL，Eppendorf PO2 直方图和电极Phe测量作为评估方法 癌症患者的预后和监测治疗。重要的是 这是在有明确规定的治疗方法的良好对照研究中完成的。 协议和明确定义的临床终端。我们预计将评估 MRS/MRI建立的治疗前和治疗后模型 STS的代谢特征也是联合HT/RT的预后因素 AS评估多参数代谢谱作为指标 治疗预后。我们还将评估这些参数是否 对于“可加热”和“不可加热”的肿瘤 治疗方案。 预测个体患者治疗反应的益处 源自这样一种概念，即可以向无响应者提供 替代疗法，如果存在这种疗法的话。这样的好处很难得到 在患者发病率和美元成本方面都夸大了。确实有 除了直接节省成本外，还有非常重要的好处：(L)不治疗 患者将免于发病率、时间和压力的无效 治疗；(2)癌症转移的机会较小 在无效的治疗期间；以及(3)替代治疗可以是 在病人的治疗过程中尝试过。

This project has successfully studied magnetic resonance imaging (MRI) and 31P spectroscopy (MRS) to assess prognosis and monitor therapeutic results in human and canine patients with soft tissue sarcomas treated with combined hyperthermia (HT) and radiation therapy (RT). There is strong rationale to look for correlated profiles of physiologic data in a defined group of tumors, both in the unperturbed state and after therapeutic intervention to improve our understanding of the physiological mechanisms of clinical response to thermoradiotherapy. Such physiologic metabolic data could greatly assist in the development and deployment of anti- neoplastic therapy, especially if this information can be shown to be independent of other known prognostic variables. Specifically, we need to be able (l) to identify, prior to therapy, those patients most likely to benefit from a specific course of therapy, (2) to identify, early during the course of therapy, nonresponding patients for whom therapy alternatives can be implemented with the greatest efficacy. The goal of this study is to continue to evaluate the usefulness of tumor physiologic profiles, as assessed by 31P MRS, 1H MRl, Eppendorf pO2 histographs, and electrode pHe measurements as methods of assessing prognosis and monitoring therapy in cancer patients. It is important that this be done in well controlled studies with clearly specified therapeutic protocols and well defined clinical endpoints. We expect to evaluate the prior developed model that MRS/MRI derived pretherapy and posttherapy metabolic characteristics of STS are prognostic for combined HT/RT as well as evaluate multiple parameter metabolic profiles as indices of therapeutic prognosis. We also will evaluate whether these parameters are consistent for "heatable" and "non-heatable" tumors in the context of the therapy protocol. The benefits of predicting therapeutic response in individual patients derive from the concept that non-responders could be offered an alternative therapy if such a therapy exists. Such benefits are hard to overstate both in terms of patient morbidity and dollar costs. There are also very important benefits beyond direct cost savings: (l) non-treated patients would be spared morbidity, time, and stress of ineffective treatment; (2) the cancer would have less opportunity to metastasize during an ineffectual treatment; and (3) alternate treatments could be tried earlier in the patient's therapy course.